Use of pain at baseline and pain progression to predict overall survival (OS) in patients (pts) with docetaxel pretreated metastatic castration-refractory prostate cancer (CRPC): Results from the SPARC trial


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Sartor, AO; Petrylak, D; Sternberg, C; Witjes, F; Halabi, S; Berry, W; Petrone, M; McKearn, T; Noursalehi, M; George, M

Published Date

  • May 20, 2009

Published In

Volume / Issue

  • 27 / 15

International Standard Serial Number (ISSN)

  • 0732-183X